Molecular mechanisms to control therapeutic vulnerabilities of gastrointestinal cancers
Schneider Lab
Our laboratory aims to understand molecular mechanisms that control therapeutic vulnerabilities of gastrointestinal cancers (e.g. pancreatic cancer, rectal cancer). Hereby, we intend to bridge pre-clinical and clinical cancer science to improve cancer treatment.
Projects
- Targeting the epigenetic machinery
- Oncogenic transcription factors
- Oncogenic signaling
- Drug Screen, Drug Repurposing, and Drug Development
- Human primary cellular cancer models
Lab-Members
Working group leader
Kontaktinformationen
- Telefon: +49 551 3920488
- E-Mail-Adresse: guenter.schneider(at)med.uni-goettingen.de
Publications
- Genetic screens identify a context-specific PI3K/p27Kip1 node driving extrahepatic biliary cancer.
C. Falcomatà, S. Bärthel,…, G. Schneider*, Dieter Saur*. Cancer Discovery (2021) DOI: 10.1158/2159-8290.CD-21-0209 * equally contributing senior authors - Mesenchymal plasticity regulated by Prrx1 alters tumor differentiation, metastatic dissemination and response to chemotherapy in pancreatic cancer.
K. Feldmann,…, G. Schneider, D. Saur, M. Reichert. Gastroenterology (2021) 160(1):346-361.e24. - Important role of Nfkb2 in the KrasG12D-driven carcinogenesis in the pancreas.
Z. Hassan, C. Schneeweis, M. Wirth, S. Müller, C. Geismann, T. Neuß, K. Steiger, O.H. Krämer, R.M. Schmid, R. Rad, A. Arlt, M. Reichert, D. Saur, G. Schneider. Pancreatology (2021) 26:S1424-3903 - Impact of DNA repair and reactive oxygen species levels on radioresistance in pancreatic cancer.
L. Nguyen, S. Dobiasch, G. Schneider,…, S. E. Combs. Radiotherapy and Oncology (2021) 159:265-276. - Cannabidiol converts NFB into a tumor suppressor in glioblastoma with defined antioxidative properties.
M.N.M. Volmar,…, G. Schneider,…, R. Glass. Neuro-Oncology (2021) DOI: 10.1093/neuonc/noab095 - The SUMO Pathway in Pancreatic Cancer: Insights and Inhibition.
C. Schneeweis,…, , G. Schneider. British J. Cancer (2021) 124:531-538. - New insights into pancreatic cancer: notes from a virtual meeting.
E. Hessmann, G. Schneider. Gastroenterology (2021) 161(3):785-791. - Identification of cytokeratin24 as a tumor suppressor for the management of head and neck cancer.
D. Gül, N. Habtemichael, D. Dietrich, J. Dietrich, D. Goesswein, A. Khamis, E. Deuss, J. Künzel, G.Schneider, S. Strieth, R. Stauber. Biological Chemistry (2021) DOI: 10.1515/hsz-2021-0287. - Class 1 Histone Deacetylases and Ataxia-Telangiectasia Mutated Kinase Control the Survival of Pancreatic Cancer Cells upon dNTP Depletion. A. Nguyen, J. Murr, Y. Yen, G. Schneider, O.H. Krämer. Cells (2021) accepted manuscript.
- Inhibition of Wnt/β-catenin signaling sensitizes esophageal cancer cells to chemoradiotherapy.
M. Spitzner, G. Emons, K. Burkhard Schütz, H.A. Wolff, S. Rieken, M. Ghadimi, G.Schneider, M. Grade. International Journal of Molecular Sciences (2021) accepted manuscript. - Rationale for MYC Imaging and Targeting in Panceratic Cancer.
G. Schneider, M. Wirth, U. Keller, D. Saur. EJNMMI Research (2021) accepted manuscript.
Funding
